TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9501748

Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitor (SSRI), paroxetine, 20 mg/day
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 7706154

Group type: EXPERIMENTAL
Intervention: Urine alarm
Number of subjects: 1
Study: 2244675

Group type: EXPERIMENTAL
Intervention: Budesonide inhalation through the nose from a pressurized aerosol attached to a spacer device
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo inhalation
Number of subjects: 30
Study: 666948

Group type: EXPERIMENTAL
Intervention: L(‐)‐bupivacaine at 7.69 mmol/l
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: D(+)‐bupivacaine at 7.69 mmol/l
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: L(‐)‐bupivacaine at 0.48 mmol/l
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: L(‐)‐bupivacaine from 0.48‐3.84 mmol/l
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: D(+)‐bupivacaine from 0.48‐3.84 mmol/l
Number of subjects: 17

Group type: COMPARATOR
Intervention: Physiological saline
Number of subjects: 17
Study: 31023759

Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanate (80 mg/kg/day, maximum 980 mg of amoxicillin in two-divided doses) for 8 days
Number of subjects: 314

Group type: COMPARATOR
Intervention: Placebo (equal volume and dosing frequency) for 8 days
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanate
Number of subjects: 314

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 314
Study: 28953325

Group type: EXPERIMENTAL
Intervention: Second-line protease inhibitor (PI)-based ART
Number of subjects: 928
Study: 25501623

Group type: EXPERIMENTAL
Intervention: MCPB system
Number of subjects: 78

Group type: COMPARATOR
Intervention: CCPB system
Number of subjects: 78
Study: 24324331

Group type: EXPERIMENTAL
Intervention: Lifestyle and functional exercise program (LiFE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Structured exercise program (control)
Number of subjects: 0
Study: 21508140

Group type: EXPERIMENTAL
Intervention: Anakinra 150 mg sc once daily for 4 weeks
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Anakinra
Number of subjects: 19
Study: 19080072

Group type: COMPARATOR
Intervention: Enalapril 10 mg (Group 1, n=153)
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: Enalapril maleate and folic acid tablet at the ratio of 10/0.4 (Group 2, n=151)
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: Enalapril maleate and folic acid tablet at the ratio of 10/0.8 (Group 3, n=152)
Number of subjects: 456
Study: 16571963

Group type: EXPERIMENTAL
Intervention: Closed-loop propofol target control infusion
Number of subjects: 164

Group type: COMPARATOR
Intervention: Manual propofol target control infusion
Number of subjects: 164
Study: 12722174

Group type: EXPERIMENTAL
Intervention: Mirtazapine 45 mg per day for 2 weeks
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo for 2 weeks
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Mirtazapine 45 mg per day
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 17
Study: 10932665

Group type: EXPERIMENTAL
Intervention: Tourniquet (Lofquist cuff, inflated to 120 mmHg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: No tourniquet
Number of subjects: 50
Study: 9298123

Group type: EXPERIMENTAL
Intervention: Somatostatin-positive dendritic cells in psoriatic lesions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Somatostatin and HLA-DR immunoreactivity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Somatostatin-positive cells
Number of subjects: 0
Study: 7939938

Group type: EXPERIMENTAL
Intervention: Fansimef 1 tab/week (group 1)
Number of subjects: 1407

Group type: EXPERIMENTAL
Intervention: Fansimef 1 tab/2 weeks (group 2)
Number of subjects: 1407

Group type: COMPARATOR
Intervention: Chloroquine 300 mg base weekly plus Fansidar 1 tab/week (group 3)
Number of subjects: 1407

Group type: EXPERIMENTAL
Intervention: Fansimef 1/2 tab/week (group 4)
Number of subjects: 1407

Group type: EXPERIMENTAL
Intervention: Lariam 1/2 tab/week (group 5)
Number of subjects: 1407

Group type: COMPARATOR
Intervention: Chloroquine plus Fansidar (group 6)
Number of subjects: 1407
Study: 3521245

Group type: EXPERIMENTAL
Intervention: Intravenous streptokinase (700,000 units)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control (normal saline solution)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Intravenous streptokinase
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control
Number of subjects: 52
Study: 29658441

Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (tDCS) combined with Cognitive Training (Cog) for 10 sessions (D0-D11)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Cognitive Training (Cog) only (sham tDCS)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (tDCS) combined with Cognitive Training (Cog)
Number of subjects: 24
Study: 27525994

Group type: EXPERIMENTAL
Intervention: Soluble suppression of tumorigenicity-2 (day 0)
Number of subjects: 826

Group type: EXPERIMENTAL
Intervention: Interleukin-6 (day 0)
Number of subjects: 826

Group type: EXPERIMENTAL
Intervention: Soluble suppression of tumorigenicity-2 (day 3)
Number of subjects: 826

Group type: EXPERIMENTAL
Intervention: Interleukin-6 (day 3)
Number of subjects: 826

Group type: EXPERIMENTAL
Intervention: Soluble suppression of tumorigenicity-2 (day 3 weaning assessment)
Number of subjects: 826

Group type: EXPERIMENTAL
Intervention: Interleukin-6 (day 3 weaning assessment)
Number of subjects: 826

Group type: EXPERIMENTAL
Intervention: Soluble suppression of tumorigenicity-2 (spontaneous breathing trial)
Number of subjects: 826

Group type: EXPERIMENTAL
Intervention: Interleukin-6 (spontaneous breathing trial)
Number of subjects: 826

Group type: EXPERIMENTAL
Intervention: Soluble suppression of tumorigenicity-2 (need for reintubation)
Number of subjects: 826

Group type: EXPERIMENTAL
Intervention: Interleukin-6 (need for reintubation)
Number of subjects: 826
Study: 24796043

Group type: EXPERIMENTAL
Intervention: Staging acupoint embedment therapy, applied twice during the menstrual cycle (3 days before menstruation and during the 12th-14th days of menstruation) using specific acupoints.
Number of subjects: 70

Group type: COMPARATOR
Intervention: Fenbid, 0.3 g orally, twice a day, starting 3 days before menstruation until pain relief, for 3 menstrual cycles.
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Staging acupoint embedment therapy
Number of subjects: 70
Study: 24490264

Group type: EXPERIMENTAL
Intervention: Oral high-dose multivitamins and multiminerals
Number of subjects: 1708

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1708
Study: 21649815

Group type: EXPERIMENTAL
Intervention: Combination of bleaching agents (glycolic acid, kojic acid, lipohydroxyacid, and Vitreoscilla extract) applied daily for 3 months
Number of subjects: 24
Study: 18294022

Group type: EXPERIMENTAL
Intervention: Active transcranial magnetic stimulation (TMS) administered 5 times per week at 10 pulses per second, at 120% of motor threshold, for a total of 3000 pulses/session.
Number of subjects: 158
Study: 17197740

Group type: EXPERIMENTAL
Intervention: Postoperative adjuvant chemotherapy (platinum-based)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Uracil-tegafur
Number of subjects: 0
Study: 14642411

Group type: EXPERIMENTAL
Intervention: Soybean oil
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Semi‐liquid margarine
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Soft margarine
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Shortening
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Traditional stick margarine
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Butter
Number of subjects: 6
Study: 11009229

Group type: EXPERIMENTAL
Intervention: Ketamine 0.5 mg/kg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ketamine 1.0 mg/kg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 9372379

Group type: EXPERIMENTAL
Intervention: Enteral diet (free amino acid and small peptide)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Parenteral support (isonitrogenous isocaloric)
Number of subjects: 30
Study: 1589282

Group type: EXPERIMENTAL
Intervention: Pharmacological therapy for acute spinal cord injury
Number of subjects: 0
Study: 3331863

Group type: EXPERIMENTAL
Intervention: 100 mg tramadol
Number of subjects: 40

Group type: COMPARATOR
Intervention: 100 mg pethidine
Number of subjects: 40
Study: 29861256

Group type: EXPERIMENTAL
Intervention: Patellar taping in addition to routine physiotherapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Routine physiotherapy (Control)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Patellar taping
Number of subjects: 30
Study: 27303100

Group type: EXPERIMENTAL
Intervention: Topiroxostat 160 mg daily
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Topiroxostat 40 mg daily
Number of subjects: 76
Study: 24115765

Group type: EXPERIMENTAL
Intervention: Behavioral weight loss intervention
Number of subjects: 31

Group type: COMPARATOR
Intervention: Bariatric surgery
Number of subjects: 31
Study: 22892753

Group type: EXPERIMENTAL
Intervention: All‐Bond SE (Bisco Inc)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: All‐Bond 3 (Bisco Inc)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: One‐Step Plus (Bisco Inc)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control
Number of subjects: 200
Study: 20819621

Group type: EXPERIMENTAL
Intervention: Rapid hemodilution (HCT < 35%, n = 56)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Slow hemodilution (HCT >= 35%, n = 59)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Rapid hemodilution (HCT < 35%)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Slow hemodilution (HCT >= 35%)
Number of subjects: 115
Study: 19082796

Group type: EXPERIMENTAL
Intervention: Xiaoshui decoction (XSD) combined with intrapleural perfusion of cisplatin
Number of subjects: 51

Group type: COMPARATOR
Intervention: Intrapleural perfusion of cisplatin (control)
Number of subjects: 51
Study: 17328449

Group type: EXPERIMENTAL
Intervention: Non-surgical management
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 14574046

Group type: EXPERIMENTAL
Intervention: Learning objectives checklist card
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no checklist card)
Number of subjects: 0
Study: 10341115

Group type: EXPERIMENTAL
Intervention: Physostigmine administered orally every 2 hr, six times per day for 10 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7745021

Group type: EXPERIMENTAL
Intervention: GnRH agonist treatment (discontinued after 4 and 10 months)
Number of subjects: 15
Study: 1904090

Group type: EXPERIMENTAL
Intervention: Intravenous glucose and total parenteral nutrition with insulin
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard intravenous therapy alone
Number of subjects: 24
Study: 7440748

Group type: EXPERIMENTAL
Intervention: Child modulator intervention for a 6‐month period
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: School informed group (teachers' ratings and achievement test scores)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Follow-up testing between modulated and school informed group
Number of subjects: 90
Study: 31876896

Group type: EXPERIMENTAL
Intervention: Atezolizumab
Number of subjects: 2110

Group type: COMPARATOR
Intervention: Docetaxel
Number of subjects: 2110

Group type: EXPERIMENTAL
Intervention: Atezolizumab and Docetaxel
Number of subjects: 2110
Study: 30657228

Group type: EXPERIMENTAL
Intervention: Referral to a paediatric specialist for treatment planning
Number of subjects: 788

Group type: COMPARATOR
Intervention: Responsibility to treat cFPM
Number of subjects: 788

Group type: COMPARATOR
Intervention: Restoration of cFPM including root canal treatment
Number of subjects: 788

Group type: EXPERIMENTAL
Intervention: Extraction of cFPM
Number of subjects: 788
Study: 27673579

Group type: EXPERIMENTAL
Intervention: Fludarabine and cytarabine (FA)
Number of subjects: 45

Group type: COMPARATOR
Intervention: High-dose cytarabine (HD-Ara-C)
Number of subjects: 45
Study: 25936545

Group type: EXPERIMENTAL
Intervention: Community Re‐engagement Cue to Action Trigger Tool (CRCATT)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Qualitative interviews
Number of subjects: 77
Study: 23307029

Group type: EXPERIMENTAL
Intervention: Maximal strength training (MST)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Conventional strength training (CON)
Number of subjects: 8
Study: 22289530

Group type: EXPERIMENTAL
Intervention: Remifentanil 4 ng/ml
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Remifentanil 6 ng/ml
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group (Remifentanil 0 ng/ml)
Number of subjects: 96
Study: 19539256

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control
Number of subjects: 97
Study: 17132474

Group type: EXPERIMENTAL
Intervention: Transdermal oxybutynin for 6 months or less
Number of subjects: 2878
Study: 15033948

Group type: EXPERIMENTAL
Intervention: Day 5/6 embryo transfer
Number of subjects: 14
Study: 11393600

Group type: EXPERIMENTAL
Intervention: Relaxation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sleep compression
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo desensitization
Number of subjects: 0
Study: 9394816

Group type: EXPERIMENTAL
Intervention: Topical corticosteroid (fluticasone propionate)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antigen challenge
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hayfever patients (out of season)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 0
Study: 2446064

Group type: EXPERIMENTAL
Intervention: Ketanserin, 10 mg i.v. or 40 mg t.i.d. orally
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ketanserin, 10 mg i.v.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Phentolamine or prazosin pretreatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Phentolamine
Number of subjects: 0
Study: 29961686

Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ) administered intravenously every 4 weeks (8 or 10 mg/kg based on weight) for 16 weeks, followed by random assignment to TCZ or placebo for 24 weeks.
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 187
Study: 27208335

Group type: EXPERIMENTAL
Intervention: Artificial Pancreas (AP)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Parent-managed sensor-augmented pump (SAP)
Number of subjects: 30
Study: 25424567

Group type: EXPERIMENTAL
Intervention: Anodal tDCS (1 mA) for 20 minutes daily over two weeks
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Anodal tDCS (1 mA)
Number of subjects: 10
Study: 23663789

Group type: EXPERIMENTAL
Intervention: Low-intensity dietary counseling (group A)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (group B)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 61
Study: 20051588

Group type: EXPERIMENTAL
Intervention: 0.5 g/kg of 20% mannitol over 15 minutes
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 1.0 g/kg of 20% mannitol over 15 minutes
Number of subjects: 22
Study: 18164501

Group type: EXPERIMENTAL
Intervention: Cortisol (50 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 17017189

Group type: EXPERIMENTAL
Intervention: Rectification group (80 sides, 64 cases) - anatomical variation dealt with during FESS
Number of subjects: 128

Group type: COMPARATOR
Intervention: Contrast group (100 sides, 64 cases) - no anatomical variation dealt with during FESS
Number of subjects: 128
Study: 14569646

Group type: EXPERIMENTAL
Intervention: Training intervention to enhance self-efficacy
Number of subjects: 0
Study: 10232508

Group type: EXPERIMENTAL
Intervention: Automated method for estimating lesion volume
Number of subjects: 20
Study: 8908230

Group type: EXPERIMENTAL
Intervention: Intravenous adrenaline (0.3 microgram/kg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Tracheal adrenaline (3 micrograms/kg)
Number of subjects: 14
Study: 1914761

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg once daily in the morning (N = 104)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Ranitidine 300 mg once daily at night (N = 106)
Number of subjects: 206
Study: 6195235

Group type: EXPERIMENTAL
Intervention: Hibiscrub (chlorhexidine)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Non-medicated soap
Number of subjects: 224
Study: 30947606

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided corticosteroid injection
Number of subjects: 104

Group type: COMPARATOR
Intervention: Landmark-based corticosteroid injection
Number of subjects: 104
Study: 29419692

Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 50
Study: 26410385

Group type: EXPERIMENTAL
Intervention: BUZZY
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control (no BUZZY)
Number of subjects: 48
Study: 24664349

Group type: EXPERIMENTAL
Intervention: 5.0 g agave inulin
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 7.5 g agave inulin
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control (0 g agave inulin)
Number of subjects: 29
Study: 23011957

Group type: EXPERIMENTAL
Intervention: Various dose levels of the intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20012022

Group type: EXPERIMENTAL
Intervention: Tyrosine/phenylalanine depletion (to reduce DA neurotransmission)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Tryptophan depletion (to reduce 5‐HT neurotransmission)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Tryptophan/tyrosine/phenylalanine depletion (to reduce DA and 5‐HT neurotransmission simultaneously)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Balanced amino acid control (no depletion)
Number of subjects: 16
Study: 18593294

Group type: EXPERIMENTAL
Intervention: HSV suppressive therapy
Number of subjects: 0
Study: 16098419

Group type: EXPERIMENTAL
Intervention: PCI
Number of subjects: 450

Group type: COMPARATOR
Intervention: CABG
Number of subjects: 450
Study: 12557801

Group type: EXPERIMENTAL
Intervention: Intravenous oxytocin plus intravaginal misoprostol (n = 36)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Intravenous oxytocin plus placebo intravaginal (n = 34)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Intravaginal misoprostol plus intravenous placebo (n = 37)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 107
Study: 9602955

Group type: EXPERIMENTAL
Intervention: Intravenous famotidine pretreatment
Number of subjects: 12

Group type: COMPARATOR
Intervention: No famotidine pretreatment (Control)
Number of subjects: 12
Study: 8003862

Group type: EXPERIMENTAL
Intervention: Modified radical mastectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Extended radical mastectomy
Number of subjects: 0
Study: 2591109

Group type: EXPERIMENTAL
Intervention: 1 alpha hydroxyvitamin D + calcium + placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 1 alpha hydroxyvitamin D + calcium + lynestrenol
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 1 alpha hydroxyvitamin D + calcium + sodium fluoride
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (matched for sex, age, disease duration and menopausal state)
Number of subjects: 60
Study: 30237262

Group type: EXPERIMENTAL
Intervention: Daratumumab plus lenalidomide/dexamethasone
Number of subjects: 0
Study: 27599225

Group type: EXPERIMENTAL
Intervention: Home-based telebehavioral health (HBTBH) via videoconferencing (VC)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Traditional in-office behavioral activation treatment for depression (BATD)
Number of subjects: 121
Study: 24762366

Group type: EXPERIMENTAL
Intervention: Dance labor (standing upright with pelvic tilt and hip movements with partner massage for a minimum of 30 minutes)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care during physiologic labor (Control)
Number of subjects: 60
Study: 22094954

Group type: EXPERIMENTAL
Intervention: Valganciclovir prophylaxis (2 × 450 mg oral valganciclovir/day for 100 days)
Number of subjects: 296

Group type: COMPARATOR
Intervention: Preemptive therapy (monitored by CMV-PCR, 2 × 900 mg valganciclovir/day for at least 14 days after positive PCR)
Number of subjects: 296
Study: 20716330

Group type: EXPERIMENTAL
Intervention: 10 preventive actions implemented by family pediatricians (promotion of breastfeeding, avoidance of solid foods, control of protein intake, avoidance of sugar‐sweetened beverages, avoidance of bottle, active means of transportation, identification of early adiposity rebound, limitation of television viewing, promotion of movement, and teaching portion size) at 10 time points during a 6‐yr follow‐up.
Number of subjects: 3610

Group type: COMPARATOR
Intervention: Usual standard of care provided by family pediatricians.
Number of subjects: 3610
Study: 18156412

Group type: EXPERIMENTAL
Intervention: 3 mg/d zinc in a liquid supplement
Number of subjects: 0

Group type: COMPARATOR
Intervention: 3 mg/d zinc in a fortified porridge
Number of subjects: 0

Group type: COMPARATOR
Intervention: No extra zinc
Number of subjects: 0
Study: 17014062

Group type: EXPERIMENTAL
Intervention: Rituximab (RTX) with methotrexate (MTX)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Methotrexate (MTX) alone
Number of subjects: 0
Study: 12956243

Group type: EXPERIMENTAL
Intervention: Standard classification learning paradigm with a common stimulus set
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Shape as a relevant dimension in categorization
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Natural language use reflecting stimulus properties
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Difficulty of mastering classification rules
Number of subjects: 0